Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases-Reference-Cited by-同舟云学术

Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases

Published:2022-08 Issue: Volume:55 Page:152023
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Schreiber Stefan^ORCID,Puig Luis,Gonçalves João,Mease Philip J.,Panaccione Remo,Emery Paul

Funder

Mylan

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference97 articles.

1. U.S. Food and Drug Administration. Biosimilar development, review, and approval. October 20, 2017. https://www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval (accessed September 11, 2020).

2. European Medicines Agency. Biosimilar medicines: overview. October 29, 2019. https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview (accessed September 23, 2020).

3. Healio. FDA approves Hulio, sixth Humira biosimilar. July 9, 2020. https://www.healio.com/news/rheumatology/20200709/fda-approves-hulio-sixth-humira-biosimilar (accessed September 14, 2021).

4. U.S. Food and Drug Administration. Biosimilar Product Information. July 29, 2021. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information (accessed September 15, 2021).

5. Ray F. Nepexto, Enbrel biosimilar, approved to treat patients in Europe. June 15, 2020. https://ankylosingspondylitisnews.com/2020/06/15/nepexto-enbrel-biosimilar-approved-eu-treat-ankylosing-spondylitis-other-inflammatory-disorders/ (accessed September 23, 2020).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases;Drug Discovery Today;2024-08

2. Regulatory Considerations of Biosimilars in Cancer;Biosimilars for Cancer Treatment;2024

3. Upadacitinib for the treatment of adult patients with active psoriatic arthritis;Expert Review of Clinical Immunology;2023-12-28

4. Biosimilars in Dermatology Review;Journal of Psoriasis and Psoriatic Arthritis;2023-11-03

5. Riding the Wave of Adalimumab Biosimilars: Considerations for Pediatric Gastroenterologists;Journal of Pediatric Gastroenterology & Nutrition;2023-03-02